Magnesium Valerate

Magnesium valerate is a magnesium salt formed by combining magnesium with valeric acid, a short-chain fatty acid. No human clinical trials exist for this specific compound, and its potential biological effects are extrapolated from related compounds such as magnesium valproate and elemental magnesium.

Origin & History

Magnesium valerate is a synthetic magnesium salt of valproic acid (2-propylpentanoic acid) with the chemical formula C10H18MgO4, classified as an organic magnesium compound. It has no natural origin and is chemically synthesized, likely by reacting magnesium oxide or hydroxide with valeric acid, similar to other pharmaceutical magnesium salts.

Historical & Cultural Context

No historical or traditional medicinal uses are recorded for magnesium valerate, as it is a modern synthetic compound without ties to traditional systems like Ayurveda or TCM. While valproic acid was synthesized in 1881 and gained use as an anticonvulsant in the 1960s, and magnesium salts have ancient uses (e.g., Epsom salts), this specific form has no traditional precedent.

Health Benefits

• No clinically proven health benefits - no human clinical trials or RCTs exist for magnesium valerate
• Related compound magnesium valproate has potential antiepileptic properties (no specific trial data available)
• Related compound magnesium valproate may have antineoplastic activity (no specific trial data available)
• General magnesium supplementation supports enzymatic reactions and ATP hydrolysis (not specific to valerate form)
• No evidence-based benefits can be claimed for magnesium valerate due to complete absence of clinical research

How It Works

Magnesium valerate theoretically delivers ionic magnesium (Mg²⁺), which acts as a cofactor for over 300 enzymatic reactions, including ATP synthesis via Mg-ATPase and NMDA receptor modulation by blocking the receptor's ion channel at rest. The valerate (pentanoate) moiety may interact with histone deacetylase (HDAC) inhibition pathways, a property observed with structurally related valproate compounds, potentially influencing gene expression and neuronal excitability. However, no pharmacokinetic or receptor-binding studies specific to magnesium valerate have been published to confirm these mechanisms in humans.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on magnesium valerate were identified in available sources, with searches yielding no PubMed PMIDs or study details for this compound. While the related compound magnesium valproate has been described with antiepileptic and potential antineoplastic properties, no specific trial data (study design, sample size, outcomes) is provided.

Clinical Summary

As of the available literature, zero human randomized controlled trials (RCTs), observational studies, or pharmacokinetic studies have been conducted specifically on magnesium valerate. Evidence for potential antiepileptic properties is extrapolated from magnesium valproate, a structurally related compound studied primarily in pediatric epilepsy populations. General magnesium supplementation research demonstrates benefits for blood pressure, insulin sensitivity, and muscle function, but these outcomes cannot be directly attributed to the valerate salt form without bioavailability data. The current evidence base is insufficient to support any specific health claim for magnesium valerate.

Nutritional Profile

Magnesium valerate is a magnesium salt of valeric acid (pentanoic acid), functioning primarily as a mineral supplement delivering elemental magnesium. Elemental magnesium content is estimated at approximately 10-15% by molecular weight, comparable to other organic magnesium salts. As an organic acid salt, magnesium valerate theoretically offers improved bioavailability over inorganic forms (e.g., magnesium oxide at ~4% absorption) due to the organic acid carrier facilitating intestinal transport via passive diffusion and transporter-mediated uptake; however, no published human bioavailability studies exist to confirm superiority over established organic forms like magnesium glycinate (~80% absorption) or magnesium citrate (~30% absorption). The valerate (C5 fatty acid) component is a short-chain fatty acid that may provide minor substrate for colonic fermentation. No meaningful macronutrient, vitamin, fiber, or protein content is present. Magnesium itself supports over 300 enzymatic reactions, ATP hydrolysis, DNA synthesis, and NMDA receptor regulation at physiological concentrations (serum reference: 0.75–0.95 mmol/L).

Preparation & Dosage

No clinically studied dosage ranges, forms (extract, powder, standardized), or standardization details exist for magnesium valerate as no trials were found. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Magnesium valerate pairs well with Vitamin B6 (pyridoxine at 10-25mg), which upregulates magnesium transport into cells via TRPM7 channel modulation, enhancing intracellular magnesium retention and amplifying its role in neurotransmitter synthesis. Taurine (500-1000mg) complements magnesium by co-regulating calcium channel activity and stabilizing cell membranes, creating additive effects on cardiovascular and neurological relaxation pathways. Vitamin D3 (1000-2000 IU) synergizes by upregulating magnesium-dependent enzymes involved in D3 metabolism (CYP2R1, CYP27B1), while magnesium reciprocally activates vitamin D receptors — a bidirectional dependency meaning each enhances the other's bioactivity. Zinc (5-10mg) should be used cautiously in stacks as high-dose zinc (>50mg) competitively inhibits magnesium absorption via shared divalent metal transporters (DMT1), so moderate, timed dosing is preferred.

Safety & Interactions

Magnesium valerate has no dedicated human safety studies, so risk assessment must rely on profiles of its components: elemental magnesium and valeric acid. Excess magnesium intake above the tolerable upper intake level of 350 mg/day from supplements can cause diarrhea, nausea, abdominal cramping, and at high doses, hypermagnesemia leading to hypotension or cardiac arrhythmia. Valproate-related compounds are known to inhibit cytochrome P450 enzymes and interact with antiepileptic drugs, anticoagulants such as warfarin, and CNS depressants, though whether valerate shares this pharmacology is unconfirmed. Use during pregnancy and breastfeeding should be avoided until safety data are available, given valproate's well-documented teratogenicity.